Researchers join in quest to stop spread of HIV

BRITTANY LAVIN FEATURES EDITOR

BLL722@CABRINI EDU

Researchers in the Philadelphia area are joining in the quest to stop to the spread of HIV. Currently, they are working to develop new vaccines that will prevent individuals from becoming infected. Researchers also hope to develop a vaccine that will be effective in treating those who are already HIV-positive.

There are two types of HIV vaccines. Therapeutic HIV vaccines are treatment vaccines and help treat people who are HIVpositive. Preventative HIV vaccines are designed to prevent people from becoming infected.

According to Hildegund C.J. Ertl, an immunologist at The Wistar Institute in Philadelphia, vaccines are developed through a series of trials. The vaccines are tested first in animals to ensure that they create a safe immune response. So far, Ertl’s research has produced strong results.

“Our vectors induce strong T- cell responses in mice and monkeys even if the animals have pre-existing antibodies to human serotype adenoviruses,” Ertl said.

Once the vaccine proves to be immunogenic in animals, they test it for contaminants before beginning trials on human subjects. First, they conduct a dose escalation trial to determine a safe and effective dose. Then they conduct a second trial in which they combine two different vaccines sequentially.

These experimental vaccines do not contain the real virus. However, some trials have been known to produce antibodies in a persons body that help fight against HIV. Though these antibodies could cause a person to test positive for HIV, it does not mean they actually have it.

Ertl and her team are currently preparing to test a new vaccine. Though she expects the research to have positive results, not all trials make it. According to an article in the Philadelphia Inquirer, Merck & Co. Inc. recently pulled the plug on a trial that was three years in the making because “it didn’t seem to be working.”

This trial was designed to see if the vaccine would prevent HIV infection and also see if it would reduce the effects in those who were already infected.

It failed, but according to Ian Frank, the director of the HIV Vaccine Trials at the University of Pennsylvania, that particular trial may still be useful.

“The information is going to help us develop vaccine in the future,” Frank told the Inquirer. “We’re really at the very earliest stages in this process.”

According to the same article, $759 million is being spent each year on vaccine trials. Thus far, there has been significant advancement in the development of these vaccines but challenges still remain. The greatest of these is how to develop a vaccine for a virus that mutates rapidly and is different in each person.

“That’s the main challenge,” Ertl said. “It’s the reason we can’t readily make vaccines that protect.”

2007-2008 Loquitur Staff/Editorial Staff

Editor in Chief Kaitlin Barr

Deputy Editor Liz Lavin

Managing Editor Nicole Osuch

News Editor Jamie Hufnagle

News Editor Ashley Cook

A & E Editor Grayce Turnbach

A & E Editor Katie Clark

Features Editor Brittany Lavin

Perspectives Editor Jillian Smith

Sports Editor Jessica Hagerty

Copy Editor Megan Pellegrino

Copy Editor Vickie Papageorge

Events Editor Diana Vilares

Adviser Dr. Jerome Zurek

Staff Writers

Jonathan Barnett

Michael Bieker

Christopher Blake

Christopher Campellone

Alicia Cook

Nicole Duggan

Danielle Feole

Laura Lombardi

Brittany McLeod

Christina Michaluk

Sarah Pastor

Nicholas Pitts

Samantha Randol

Christy Ross

Liz Garrett Meghan Smith

Christine Graf

Jessica Storm

Jessie Holeva Mallory Terrence

Danielle Kaine

Robert Kallwass

Shannon Keough

Lauren Townsend

Diana Trasatti

Jake Verterano

Ryan Kirby Britany Wright

Our Mission Statement

The Loquitur is Cabrini’s College weekly, student-run, campus newspaper. It is widely respected as the voice of students, staff, faculty, alumni and many others outside the Cabrini community. The Loquitur has earned its position by advocating for self expression through freedom of speech, and by serving as an outlet for readers to affect change on campus and off.

Founded in 1959, the Loquitur has thrived and greatly expanded its readership. The paper now has over 2,000 online readers and 1,500 print readers on a weekly basis.

Our mission is to provide readers with an opportunity to voice their opinions freely, in an environment where their voices are effectively heard and respected.

The Loquitur: You Speak. We Listen

Loquitur is a laboratory newspaper written, edited and produced by the students of COM 353, 352, 250 and 251. Subscription price is $25 per year and is included in the benefits secured by tuition and fees. Additional copies are $1 each. Loquitur welcomes letters to the editors. Letters to the editor are to be less than 500 words. These are usually in response to a current issue on campus or community area. Guest columns are longer pieces between 600 and 800 words and also are usually in response to a current issue on Cabrini College campus or community. Letters to the editor and guest columns are printed as space permits. Submissions may be edited for length, clarity and content. Name, phone number and address should be included for verification purposes. Personal attacks and anonymous submissions will not be printed. Letters to the editor and guest columns can be